Gordon Gary B. 4

What Happened Director Gary B. Gordon received three awards from TriSalus Life Sciences (TLSI) on May 14, 2026: 28,201 restricted stock units (RSUs), 24,553 RSUs elected in lieu of cash retainer, and a derivative award covering 56,403 shares (an option). All grants were reported at $0.00 per share (awards/compensation), for a combined total of 109,157 underlying shares; there was no immediate cash payment.

Key Details

• Transaction date: May 14, 2026; Form 4 filed May 15, 2026 (timely).
• Transaction type: A = Award/Grant (RSUs and a derivative option), reported at $0.00.
• Specific grants and vesting:
  • 28,201 RSUs (F1) — fully vest on May 14, 2027, subject to continued service.
  • 24,553 Retainer RSUs (F2) — elected in lieu of 2026 board cash retainer; vest quarterly in equal one‑third installments through the remainder of 2026, subject to continued service.
  • 56,403 derivative award (option) (F3) — vests in full on May 14, 2027, subject to continued service.
• Shares owned after transaction: Not specified in the provided filing details.
• Filing timeliness: Reported the next day (no late filing indicated).

Context These are compensation grants (RSUs and an option) rather than open‑market purchases or sales. RSUs convert into common shares upon vesting; the derivative award is an option-style grant that vests in one year. Such awards are routine director compensation and do not by themselves indicate buying or selling intent in the market.